Atria Investments Inc Purchases 4,772 Shares of Johnson & Johnson $JNJ

Atria Investments Inc grew its position in Johnson & Johnson (NYSE:JNJ) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 246,825 shares of the company’s stock after buying an additional 4,772 shares during the period. Johnson & Johnson comprises about 0.6% of Atria Investments Inc’s portfolio, making the stock its 26th biggest holding. Atria Investments Inc’s holdings in Johnson & Johnson were worth $51,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in the business. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson during the third quarter worth approximately $26,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. DecisionPoint Financial LLC lifted its position in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares during the last quarter. Family CFO Inc bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC grew its stake in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after buying an additional 49 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on JNJ shares. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday. Finally, Rothschild & Co Redburn increased their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Price Performance

JNJ stock opened at $230.43 on Thursday. The firm has a 50 day moving average of $235.82 and a 200-day moving average of $221.47. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The firm has a market capitalization of $554.69 billion, a P/E ratio of 26.64, a price-to-earnings-growth ratio of 2.20 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter last year, the business posted $2.77 earnings per share. The firm’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is presently 60.12%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform” and lifted its price target to $265 from $252, citing accelerating growth prospects from new drug launches and stronger oncology and immunology franchises. Johnson & Johnson upgraded at Leerink on growth prospects
• Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including Tremfya and newly approved Icotyde as key drivers for immunology growth as Stelara faces biosimilar pressure, reinforcing the company’s post-Stelara strategy. Tremfya, Icotyde Lead J&J’s Post-Stelara Immunology Strategy
• Positive Sentiment: J&J also announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, adding another product launch that supports its cardiovascular growth story. Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
• Neutral Sentiment: J&J remains in focus as a defensive, high-quality name with one of the market’s strongest credit ratings, which may keep income-focused investors interested but is less likely to be a near-term catalyst. The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
• Neutral Sentiment: The company also got attention in articles emphasizing its safety, dividend appeal, and retirement-portfolio status, which supports the stock’s defensive reputation rather than signaling a major fundamental change. Russell 1000 Dividend ETF Hits 125 as Johnson & Johnson Leads The Safety Test

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.